inhibitor

(redirected from Topoisomerase I)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: deterrent
References in periodicals archive ?
[sup][18] To the best of our knowledge, no report has elucidated the role of deoxyribonucleic acid (DNA) topoisomerase I inhibitors in cancer-initiating cells.
Hecht, "On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex," Biochemistry, vol.
Camptothecins with their docking score of their antineoplatic, topoisomerase I inhibitory, DNA intercatalor activity are shown in Tables 1,2 and 3.
In preclinical studies XR11576 has shown a significantly improved biological profile when compared with first generation dual topoisomerase I and II inhibitors, including oral bioavailability and a marked enhancement of potency.
Determination of the Binding Capacity of Topoisomerase I to the [[sup.32]P]-labeled Oligonucleotide
Autoantibodies to topoisomerase I (Sc17O): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay.
Abbreviations: CPT, camptothecin; DMSO, dimethylsulphoxide; EtBr, ethidium bromide; m-AMSA, amsacrine; MTT, 3-(4,5-dimethyl thiazol-2yl)-2,5-diphemyltetrazolium bromide; Nck, nicked; Rely relaxed; Sc, supercoiled; Topo I, topoisomerase I; Topo II, topoisomerase II.
It was reported yesterday that the contract has been signed for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate that inhibits topoisomerase I (Topo-I).
The assay uses the company's biomarker development platform to provide concurrent in-vitro identification of antibodies against domains of Scl-70 (topoisomerase I), CENP-B, KDM6B and BICD2, within human serum or plasma.
Stehlin Foundation has synthesised the analogue of the topoisomerase I inhibitor CZ48 from Camptothecin.
According to the company, Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class.
The compound is a next generation, targeted topoisomerase I inhibitor currently in Phase III development as a potential treatment for patients with locally recurrent or metastatic breast cancer.